In a bid to bolster its neurology pipeline, UCB has agreed to enter an early drug discovery collaboration with Aitia Bio. Through the deal, UCB will leverage Aitia Bio’s causal artificial intelligence (AI) simulation technology, REFS™, for the discovery of new targets and drug candidates for Huntington’s disease. The collaboration grants validation for Aitia Bio’s technology as well as provides UCB with the opportunity to investigate a new neurology indication and develop new medicines through AI.